3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
6
Phase 1/2
2
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
Doxorubicin
25
Ifosfamide
22
Radiotherapy
17
Etoposide
11
Vincristine
10
Cyclophosphamide
10
Filgrastim
8
Dactinomycin
8
Trabectedin
7
Chemotherapy, Adjuvant
5
pazopanib
4
Cisplatin
4
Topotecan
3
Radiation
3
Neoadjuvant Therapy
3
Irinotecan
3
Granulocyte Colony-Stimulating Factor
3
Dacarbazine
3
sargramostim
2
etoposide phosphate
2
eribulin
2
Observation
2
Methotrexate
2
Mesna
2
Imatinib Mesylate
2
Gemcitabine
2
Epirubicin
2
Docetaxel
2
Dexrazoxane
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Sarcoma
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts